HAVCR2 and non-small cell lung carcinoma: For example, M-MDSC have been shown to exert their immunosuppressive capacity via the immune-regulatory TIM-3/galectin-9 pathway that could mediate the resistance to PD-1 blockade in NSCLC patients [42].